谷氨酸抗剂可能会保持肺癌在检查中
Eliot B Blatt1, Ralph J DeBerardinis1,2
1Children's Research Institute, UT Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390, USA.
Science advances
|March 27, 2024
概括
谷氨胺对抗剂DRP-104抑制氨酸合成,增强免疫系统与检查点抑制剂一起使用时抗击KEAP1/NRF2突变肺癌的能力.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- KEAP1/NRF2突变在肺癌中很常见,导致抗氧化剂反应受损并促进瘤生长.
- 检查点抑制剂在某些肺癌中已经显示出有效性,但耐药性仍然是一个挑战.
- 准代谢途径提供了一种新的策略,以克服耐药性并增强抗瘤免疫力.
研究的目的:
- 为了研究谷氨胺抗剂DRP-104与检查点抑制剂结合的疗效.
- 确定DRP-104对KEAP1/NRF2突变肺癌模型中的纯素合成和抗瘤免疫的影响.
主要方法:
- 使用KEAP1/NRF2突变肺癌细胞系和患者衍生的异种移植.
- 用DRP-104作为一种谷氨酸抗剂来阻断氨酸合成.
- 结合DRP-104治疗与检查点抑制剂 (例如,抗PD-1).
- 评估瘤生长,免疫细胞透和细胞因子概况.
主要成果:
- DRP-104有效地阻断了癌细胞中的纯素合成.
- 与单独治疗相比,DRP-104和检查点抑制剂的组合显著抑制了瘤生长.
- 在用组合疗法治疗的瘤中观察到细胞毒性T淋巴细胞的增强透和激活.
- DRP-104治疗调节了瘤的微环境,使其更有利于免疫攻击.
结论:
- DRP-104,通过抑制氨酸合成,与检查点抑制剂协同作用,促进强大的抗瘤免疫力.
- 这种组合策略对治疗KEAP1/NRF2突变肺癌患者具有前景.
- 向谷氨胺代谢是克服肺癌免疫疗法耐药性的可行方法.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.9K
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.1K
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
162
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
162
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
200
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
200
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
281
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
281
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
173
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
173
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K